News headlines about Moleculin Biotech (NASDAQ:MBRX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Moleculin Biotech earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.9613267635111 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Moleculin Biotech (NASDAQ:MBRX) traded up $0.07 during mid-day trading on Tuesday, hitting $1.69. 191,500 shares of the stock traded hands, compared to its average volume of 1,346,646. Moleculin Biotech has a one year low of $0.71 and a one year high of $3.75.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter.

Separately, ValuEngine raised shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.

COPYRIGHT VIOLATION WARNING: “Moleculin Biotech (MBRX) Earns Daily Media Sentiment Score of 0.24” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/moleculin-biotech-mbrx-earns-daily-media-sentiment-score-of-0-24/1703427.html.

In other news, major shareholder Waldemar Priebe sold 100,000 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $1.70, for a total value of $170,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 20.80% of the stock is owned by insiders.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Insider Buying and Selling by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.